Samsung Bioepis and Teva Expand SB41 and SB44 Biosimilar Partnership | Lucid Diligence Brief
This Lucid Diligence Brief explores Samsung Bioepis’ expansion of its…
Rare Diseases Strategic Roundup: From Approval To Access | Aug 12 - Sep 16, 2026
Rare Disease Strategic Roundup exploring Developments and Competitive Shifts…
Lundbeck Expands EVERSANA AI Commercialization | Lucid Diligence Brief
Lundbeck Expands EVERSANA AI Across Its U.S. Commercial Organization…
Curium Lantheus Merger | Lucid Diligence Brief
Curium’s proposed acquisition of Lantheus reshapes the radiopharmaceutical…
Genprex Roche Diagnostics TROP2 Collaboration | Lucid Diligence Brief
Genprex and Roche Diagnostics begin TROP2 assay validation to support…
Harbour BioMed and Sinopharm Innovation Consortium Expands Biologics Strategy | Lucid Diligence Brief
Harbour BioMed partners with Sinopharm to establish an innovation consortium…
Obesity Strategic Roundup | June 22–July 27, 2026
Obesity Strategic Roundup exploring Developments and Competitive Shifts…
AI perception of JAK Inhibitors in Atopic Dermatitis | LucidScope AI Visibility Audit
Key Findings from the LucidScope AI Visibility Analysis Rinvoq dominates AI…
Warburg Pincus PANTHERx Rare Acquisition | Lucid Diligence Brief
Warburg Pincus to acquire control of PANTHERx Rare, backing expansion of the…
United Therapeutics’ Thymmune acquisition | Lucid Diligence Brief
United Therapeutics adds Thymmune’s iPSC thymic-cell platform to its…
Insilico Takeda AI Drug Discovery Deal | Lucid Diligence Brief
Insilico and Takeda test whether Pharma.AI can convert discovery speed into…
SERB–Hansa Idefirix Deal | Lucid Diligence Brief
SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…